

Accepted Manuscript

---

This is an Accepted Manuscript of the following article:

Carsten Ulrich Schwermer, Pawel Krzeminski, Aina Charlotte Wennberg, Christian Vogelsang, Wolfgang Uhl; Removal of antibiotic resistant E. coli in two Norwegian wastewater treatment plants and by nano- and ultra-filtration processes. *Water Sci Technol* 28 February 2018; 77 (4): 1115–1126. doi: <https://doi.org/10.2166/wst.2017.642>

©IWA Publishing 2018. The definitive peer-reviewed and edited version of this article is published in *Water Science and Technology*, 77 (4), pages 1115-1126, 2018, doi: <https://doi.org/10.2166/wst.2017.642> and is available at [www.iwapublishing.com](http://www.iwapublishing.com).

It is recommended to use the published version for citation.

---

# 1 Removal of antibiotic resistant *E. coli* in two Norwegian wastewater treatment plants and by nano- 2 and ultra-filtration processes

3 Carsten Ulrich Schwermer<sup>\*,#</sup>, Pawel Krzeminski<sup>\*</sup>, Aina Charlotte Wennberg<sup>\*</sup>, Christian Vogelsang<sup>\*</sup>,  
4 Wolfgang Uhl<sup>\*</sup>

5 <sup>\*</sup> Norwegian Institute for Water Research, Gaustadalléen 21, N-0349, Oslo, Norway

6 <sup>#</sup> Corresponding author: carsten.schwermer@niva.no

## 8 Abstract

9 The effectivity of different treatment stages at two large wastewater treatment plants (WWTPs)  
10 located in Oslo, Norway, to remove antibiotic resistant *Escherichia coli* from municipal wastewater  
11 was investigated. The WWTPs were effective in reducing the total cultivable *E. coli*. The *E. coli* in WWTP  
12 samples were mainly resistant to ampicillin (6–27%) and trimethoprim-sulfamethoxazole (5–24%),  
13 and, to a lesser extent, tetracycline (3–14%) and ciprofloxacin (0–7%). In the first WWTP, a clear  
14 decrease in the percentage of *E. coli* resistant to these antibiotics was found, with the main removal  
15 occurring during physical/chemical treatment. In the second WWTP, the percentage of cultivable  
16 resistant *E. coli* did not display a considerable change. During lab-scale membrane filtration of WWTP  
17 effluents using ultrafiltration (UF) and nanofiltration (NF) membranes, all *E. coli*, including those  
18 resistant to antibiotics, were removed completely. The results imply that UF and NF processes are  
19 potent measures to remove antibiotic resistant bacteria (ARB) during post-treatment of WWTP  
20 effluents, thus reducing the potential spread of antibiotic resistance in the receiving aquatic  
21 environment.

## 22 Keywords

23 Antibiotic resistant *E. coli*; contaminants of emerging concern (CEC); membrane filtration; wastewater  
24 treatment plant (WWTP) effluent polishing; wastewater treatment

## 25 Introduction

26 Antimicrobial resistance (AMR) is a major emerging threat to water quality and human health globally  
27 (WHO 2014). Yet, in Norway it is still regarded as a limited problem with respect to clinically important  
28 microorganisms, and at this point, is considered under control (ECDC 2014; NORM/NORM-VET 2015).  
29 Urban wastewater treatment plants (WWTPs) in which sub-therapeutic concentrations of resistance-  
30 driving antibiotics, biocides, and metals continuously co-occur with a high density of diverse  
31 microorganisms, are potential hotspots for antibiotic-resistant bacteria (ARB) as well as for horizontal  
32 gene transfer (Michael *et al.* 2013; Rizzo *et al.* 2013). Thus, the ecologically competitive and  
33 challenging environment in biological treatment stages of WWTPs potentially contributes to (i) the  
34 selection of present antibiotic resistance genes (ARGs); (ii) the creation of novel ARGs; (iii) the release  
35 of resistance-driving chemicals; (iv) the dispersal of AMR into the receiving water (Michael *et al.* 2013;  
36 Berendonk *et al.* 2015). It is increasingly recognized that WWTP discharges pose a major  
37 anthropogenic source of ARGs being released into the environment. Concurrently, WWTPs are  
38 important nodes where the spread of antibiotic resistance can be controlled/improved before the  
39 effluent is disposed to the water body or reused (Riquelme Breazeal *et al.* 2013).

40 Due to the lack of routine monitoring, little is known about the abundance, fate, and removal of both  
41 ARB & ARGs in full scale WWTPs (Rizzo *et al.* 2013; Colque Navarro *et al.* 2014; Berendonk *et al.* 2015).

*Abbreviations:* Amp, ampicillin; AOP, advanced oxidation processes; ARB, antibiotic resistant bacteria; ARG, antibiotic resistance gene; BEVAS, Bekkelaget Vann AS; CEC, contaminants of emerging concern; CFU, colony forming unit; Cip, ciprofloxacin; COD, chemical oxygen demand; Da, Dalton; DDD, defined daily doses; DN, denitrification;  $K_D$ , sorption coefficient; LOQ, level of quantification; MF, microfiltration; MIC, minimal inhibitory concentration; MPN, most probable number; N, nitrification; NF, nanofiltration; RO, reverse osmosis; SP, Sampling point; Tet, tetracycline; Tmp/Smx, trimethoprim-sulfamethoxazole; UF, ultrafiltration; VEAS, Vestfjorden Avløpssekskap; WWTPs, wastewater treatment plants.

42 In Norway, antibiotic resistance in human health care and veterinary medicine has been stringently  
43 monitored for many years, and is regulated through national strategies and action plans (NIPH 2015;  
44 NMHCS 2015; NORM/NORM-VET 2015). Despite antimicrobial policies in healthcare and food  
45 production seeming to appear successful, this situation is believed to rapidly change if antibiotic  
46 consumption and import of ARB from abroad increases (ECDC 2014; NORM/NORM-VET 2015). In fact,  
47 increase of resistant pathogens in Norway is already registered (ECDC 2014). However, due to focus  
48 on clinical microbes, the role, relevance, and potential risks of antibiotic resistance in environmental  
49 settings, including WWTPs, has received very little attention. This may also explain the lack of research  
50 related to this topic in Norway. While a few pharmaceuticals were quantified in the effluent of two  
51 major Oslo City hospitals, along with influent, sludge, and final effluent at the effluent receiving WWTP  
52 (Thomas *et al.* 2007b; Langford & Thomas 2009), systematic studies on ARB & ARGs, most of which  
53 are part of international antibiotic resistance screening programs (NORMAN Network<sup>1</sup>, NEREUS COST  
54 Action<sup>2</sup>, StARE project<sup>3</sup>), have only recently been initiated (Tiodolf *et al.* 2013).

55 The recent implementation of Europe's One Health action plan (COM 2017) that recognizes the close  
56 interconnection of human and animal health acknowledges the environment as another important  
57 contributor to the development and spread of AMR in humans and animals. To close knowledge gaps  
58 on the role of AMR in the environment, the action plan calls for an increased effort into monitoring  
59 AMR in environmental settings, and development of risk assessment methodologies that evaluate  
60 risks of AMR to human and animal health. In addition, it requests the development of technologies  
61 that reduce the spread of AMR in wastewater (COM 2017).

62 Until recently, the research focus of WWTPs has been describing the abundance and relative change  
63 of antibiotic resistance in raw and treated wastewater. Little is known about how the treatment  
64 process and operational conditions in WWTPs influence ARB removal and ARG transfer. Like other  
65 contaminants of emerging concern (CEC), including pharmaceuticals and personal care products, the  
66 fate and spread of ARB & ARGs is expected to be dependent on the type of treatment  
67 process/technology applied at each plant (Rizzo *et al.* 2013). It will also be influenced by other factors  
68 such as water quality, seasons, climate conditions, and geographical location. Thus, the improvement  
69 or upgrading of WWTPs to minimize AMR contamination of the receiving water calls for an  
70 understanding of what degree the concentration of ARB & ARGs is decreased in WWTPs, or whether  
71 they might even proliferate in such plants. Assuming that 85% of all antibiotics used by humans occurs  
72 at private households (NORM/NORM-VET 2015), of which most end up into the municipal sewage  
73 network, this calls for measures to eliminate antibiotic resistance from wastewater at WWTPs. Such  
74 measures are currently not in place because the actual risk resulting from ARB & ARGs is basically  
75 unknown. Moreover, conventional WWTPs are not designed to completely remove antibiotics and  
76 ARB & ARGs.

77 Advanced treatment technologies and disinfection downstream of the conventional biological process  
78 could provide further inactivation of ARB and removal of ARGs from WWTP effluents. Those  
79 technologies include the addition of chemical oxidants and disinfectants, UV-C irradiation, ozonation,  
80 advanced oxidation processes (AOP), adsorption, and membrane filtration processes. The latter  
81 include microfiltration (MF), ultrafiltration (UF), nanofiltration (NF), and reverse osmosis (RO), which  
82 may provide a potent alternative for ARB & ARG removal. While only a few studies have investigated  
83 the effect of MF or UF on the removal of ARB & ARGs from real wastewater (Bockelmann *et al.* 2009;

---

<sup>1</sup> Network of reference laboratories, research centers and related organizations for monitoring of emerging environmental substances, <http://www.norman-network.net>

<sup>2</sup> New and emerging challenges and opportunities in wastewater reuse (ES 1403), <http://www.nereus-cost.eu>

<sup>3</sup> Water JPI Stopping antibiotic resistance revolution, <https://stareurope.wordpress.com>


84 Riquelme Breazeal *et al.* 2013), the effects of NF and RO membrane filtration, either alone or  
85 combined with other methods, on ARB & ARG removal from WWTP effluent has not been explored.  
86 The first objective of this study was to quantify cultivable *Escherichia coli* exhibiting resistance to four  
87 selected antibiotics commonly used for medication at Norwegian hospitals; namely ampicillin (Amp),  
88 ciprofloxacin (Cip), tetracycline (Tet), and trimethoprim-sulfamethoxazole (Tmp/Smx), in samples  
89 collected at different treatment stages from two Oslo City WWTPs. This allows to evaluate the  
90 effectivity of the treatment stages to decrease the concentration of ARB, and ultimately on the risk  
91 potential of spread of antibiotic resistance to the Oslofjord. The implementation of tertiary  
92 disinfection technologies to prevent ARB release by conventional WWTPs requires the investigation  
93 of the potential effectiveness, amongst other factors. In the search of feasible methods, membrane  
94 filtration processes pose a potent alternative worthy of further exploration. Hence, the second  
95 objective was to evaluate the efficiency of UF and NF in removal of cultivable *E. coli* resistant to the  
96 selected antibiotics from WWTP effluents. Based on these results, the feasibility of UF and NF for ARB  
97 & ARG removal during post-treatment at full-scale can be explored.

## 98 **Methods**


99 **Description of WWTPs.** Water samples were collected at two full-scale municipal WWTPs in Oslo,  
100 Norway, where wastewater was treated mechanically, chemically, and biologically. As the final  
101 biological treatment step, Vestfjorden Avløpsselskap (VEAS) WWTP applied a biofilm process while  
102 Bekkelaget Vann AS (BEVAS) WWTP used an activated sludge process and dual media filtration (Figure  
103 1).

104 VEAS WWTP is Norway's largest WWTP receiving municipal wastewater from a population of 600,000  
105 in both the Oslo and Akershus county areas. The plant receives 100–110 million m<sup>3</sup> of urban  
106 wastewater annually, including sewage from five major hospitals in the Oslo area. Coagulant and  
107 polymer are added during the chemical precipitation-sedimentation process. The chemically  
108 enhanced primary treatment is followed by a two-stage biofilm process with post-denitrification  
109 (Figure 1). The biological system consists of nitrification and denitrification fixed-film processes  
110 (BIOFOR®, Degremont), using expanded clay aggregates (Leca, Norway) as medium, with methanol  
111 addition to the denitrification stage. The total hydraulic retention time in the plant is 4 h. The sludge  
112 is treated by anaerobic digestion and drying. The effluent water is discharged into the Oslofjord at a  
113 depth of 30–55 m.

114 BEVAS WWTP is Norway's second largest WWTP serving a population of about 290,000 person  
115 equivalents living in the eastern and south eastern parts of Oslo. The plant has an average daily flow  
116 of 100,000 m<sup>3</sup>/d and a maximum capacity of 260,000 m<sup>3</sup>/d. The plant annually receives about  
117 40 million m<sup>3</sup> of urban (70% of chemical oxygen demand [COD] load) and light industrial wastewater  
118 (30% of COD load; brewery, abattoir, dairy). The raw influent is pre-treated by 3 mm sieving screen,  
119 sand- and fat-trap and pre-sedimentation (Figure 1). The chemically enhanced precipitation-  
120 sedimentation process is applied only at higher flow rates, i.e., above the dry weather flow of 2.0 m<sup>3</sup>/s.  
121 Biological treatment, based on activated sludge process combined with simultaneous precipitation  
122 with iron sulfate, is followed by dual media sand filters. The dual media filters contain Filtralite MC  
123 size 2.5–4 mm (top-layer) and fine-grained sand with particle size of 1.2–2.0 mm (bottom-layer). The  
124 hydraulic retention time in the biological treatment unit is approximately 16 h, with 23 h total  
125 hydraulic retention time. The plants effluent is discharged at a 50 m depth into the Oslofjord.



a) VEAS WWTP



b) BEVAS WWTP

Figure 1. Simplified flow sheet of (a) VEAS and (b) BEVAS WWTPs. SP = Sampling point; N = Nitrification; DN = Denitrification (Figure b was adapted and modified from Storhaug 2014).

126

127 **Sample collection.** Automated 24 h composite samples were collected at the WWTPs from the  
 128 influent, after the sedimentation/activated sludge and settling step, and the final effluent (Figure 1).  
 129 Influent water at VEAS WWTP contained backwash water from biofilters and from internal return flow  
 130 from the sludge treatment. Samples were taken during October 2014 (VEAS) and February 2015  
 131 (BEVAS). Samples were transported to the laboratory for immediate experimental analyses.

132

133 **Membrane filtration tests.** WWTP effluents were subjected to membrane filtration to elucidate the  
 134 impact of membrane filtration on ARB removal. A bench scale membrane testing apparatus was used  
 135 to evaluate three commercially available membranes in the UF and NF range (Table 1). An effective  
 136 membrane area of 99.4 cm<sup>2</sup> was used by cutting pieces of different flat sheet and spiral wound  
 137 membranes obtained from the manufacturer. Test were done in cross-flow mode at constant pressure  
 138 of 1–2 bar (UF) and 6–7 bar (NF) until a volume of 1.4 L of permeate was obtained. Details about the  
 139 test system and experimental conditions are described elsewhere (Krzeminski *et al.* 2017).

140

141 Table 1. Specifications of assessed membranes. UF = Ultrafiltration; NF = Nanofiltration; Da = Dalton.

| Membrane | Filtration spectrum | Molecular weight cut off (Da) | Producer and brand name | Material                             |
|----------|---------------------|-------------------------------|-------------------------|--------------------------------------|
| UF       | UF                  | 10.000                        | Alfa Laval, UFX-10pHt   | Polysulphone permanently hydrophilic |
| NF#1     | NF                  | 200–400                       | DOW, NF270              | Polyamide thin-film composite        |
| NF#2     |                     | 150                           | Toray, TM600            | Piperazine polyamide composite       |

142

143 ***E. coli* quantification and antimicrobial susceptibility assay.** *E. coli* were cultured on Difco MI agar  
 144 plates with and without added antibiotics. Difco MI agar was prepared in sterile Milli-Q water  
 145 according to the manufacturer's instruction (Becton Dickinson). The agar was autoclaved (121°C, 15  
 146 min) and cooled to 45°C in a water bath. The respective antibiotic compound (all purchased at Sigma-  
 147 Aldrich) was added to the agar from stock solutions (dissolved in either sterile Milli-Q water, Dimethyl  
 148 sulfoxide, or methanol) to the final concentrations stated in Table 2. These antibiotic concentrations  
 149 represent the minimal inhibitory concentration (MIC) breakpoint concentrations for testing with *E.*  
 150 *coli* recommended by the Clinical and Laboratory Standards Institute (CLSI 2003, 2012) and as reported  
 151 elsewhere (Watkinson *et al.* 2007). In addition, Cefsulodin, an inhibitor of gram-positive and some  
 152 non-coliform gram-negative organisms, was added (5 µg/mL) to all plates (Brenner *et al.* 1996). The  
 153 medium was mixed well and the agar was instantly dispensed into sterile petri dishes. Control agar  
 154 plates contained no antibiotics except for Cefsulodin.

155  
 156 Table 2. Antibiotics being tested and minimal inhibitory concentration (MIC) breakpoint concentrations used.  
 157 ATC = Anatomical Therapeutic Chemical classification

| Antibiotics  | ATC group   | MIC breakpoint (µg/mL)  | Sorption coefficient K <sub>D</sub> (L/kg) primary sludge <sup>(4)</sup> |
|--|---|---|--|
| Trimethoprim/<br>Sulfamethoxazole<br>(CAS 738-70-5/723-46-6) | J01EE<br>Combinations of sulfonamides and<br>trimethoprim | 4/76 <sup>(1)</sup>   | 427/3.2  |
| Ciprofloxacin<br>(CAS 85721-33-1)                            | J01MA02<br>Fluoroquinolones                               | 4 <sup>(2)</sup>  | 2512   |
| Ampicillin<br>(CAS 69-53-4)                                  | J01CA01<br>Penicillins with extended spectrum             | 32 <sup>(2)</sup>   | --   |
| Tetracycline<br>(CAS 60-54-8)                                | J01AA<br>Tetracyclines                                    | 16 <sup>(2)</sup>   | 8400   |
| Cefsulodin<br>(CAS 52152-93-9)                               | J01DD03<br>Third-generation cephalosporin<br>antibiotic   | No breakpoint<br>concentration. Added<br>to 5 µg/mL final<br>concentration <sup>(3)</sup> . | --   |

159 <sup>1</sup>CLSI 2012; <sup>2</sup>CSLI 2003; <sup>3</sup>Watkinson *et al.* 2007; <sup>4</sup>Eslamian

160 The antibiotic susceptibility analysis was carried out as reported elsewhere (Watkinson *et al.* 2007).  
 161 For each water sample, two parallel dilution series (in phosphate buffered saline) were filtered  
 162 through cellulose nitrate membrane filters (Sartorius, Göttingen, Germany) with 0.22 µm pore size.  
 163 Dilutions between 10<sup>-1</sup> and 10<sup>-4</sup> were filtered together with 10 mL of sterile peptone water (10 g  
 164 peptone/L and 5 g NaCl/L). The membrane filters were transferred onto dishes with and without  
 165 (control; cefsulodin) antibiotics, followed by incubation for 24 h at 35°C. Blue colonies were then  
 166 counted under ambient light, and the results were confirmed at 366 nm UV light. The total  
 167 concentration of cultivable *E. coli* was obtained from control dishes. The percentage of resistance for  
 168 each antibiotic was calculated by relating the colony forming unit (CFU) counts on antibiotic-  
 169 containing plates with the CFU counts on the control plates without antibiotics according to equation  
 170 1. The limit of detection was 10 CFU/mL.


171

$$\% \text{ resistance} = \frac{\text{CFU/mL in medium with antibiotics}}{\text{CFU/mL in medium without antibiotics}} \times 100 \quad \text{Eq. 1}$$


172 In addition to the plating method, the total concentration of viable *E. coli* was quantified using the  
 173 most probable number (MPN) Colilert Quanti-Tray/2000 method (LOQ: 1 organism/100 mL; IDEXX  
 174 Laboratories, Inc.) according to ISO 9308-2:2012.

175 **Results and Discussion**

176 **Abundance of *E. coli* in WWTPs.** The total concentration of viable *E. coli* decreased considerably (>  
177 2.2 log) across the treatments at both WWTPs (Figure 2). Most *E. coli* entering VEAS WWTP were  
178 removed by the biofilm process (ca. 2 log), while at BEVAS WWTP, they were gradually removed across  
179 the entire treatment process. However, as expected, no full disinfection was achieved at either plant.  
180 Results obtained by the plating method (LOQ: 10 CFU/mL) were within the 95% confidence interval of  
181 the Colilert MPN method (LOQ: 1 CFU/100mL) (Figure 2).



a) VEAS WWTP




b) BEVAS WWTP


Figure 2. Concentration of total viable *E. coli* in samples collected at (a) VEAS and (b) BEVAS WWTPs. Concentrations were measured by the plating method (open symbols) and by Colilert MPN (closed symbols). Error bars represent 33% confidence interval, CI, (n=2) for plating method; 95% CI for a single measurement, as given by the manufacturer, for the Colilert method.



184 **Decrease in the concentration of antibiotic resistant *E. coli* in WWTPs.** The percentage of cultivable  
 185 *E. coli* resistant to the four investigated antibiotics in the influent was comparable in both WWTPs  
 186 (Figure 3).



a) VEAS WWTP



b) BEVAS WWTP

Figure 3. Percentage of antibiotic resistant *E. coli* in samples collected at (a) VEAS and (b) BEVAS WWTPs. Columns represent average measurements with error bars representing 33% confidence interval (n=2).

187

188 Given that VEAS WWTP receives sewage from several hospitals in the Oslo area (with total capacity of  
 189 ca. 2100 beds) and BEVAS WWTP receives no hospital sewage, the comparable percentage of  
 190 antibiotic resistant *E. coli* in the inlet of both facilities implies that the main source of resistance to all

191 antibiotics may not be linked to hospital discharges but rather, other sources. In fact, diffuse sources,  
 192 and mainly urban household effluent, have been reported to be the major source of ARB in municipal  
 193 WWTP influents, while hospital effluents contribute usually less than 1% of the total amount of  
 194 municipal sewage (Kümmerer 2004). Hospital inputs of resistance-driving substances to the municipal  
 195 sewers system are relatively small (Verlicchi *et al.* 2012), with the exception of a very limited number  
 196 of compounds and sporadic incidences of elevated concentrations in hospital discharged effluents, as  
 197 described for VEAS WWTP (Thomas *et al.* 2007a; Langford & Thomas 2009). Thomas and coauthors  
 198 (2007a) showed that two large Oslo City hospitals, Rikshospitalet and Ullevål, only contribute to the  
 199 general pharmaceutical load from domestic effluent received at VEAS WWTP. On the other hand, 85%  
 200 of the total sales of human antibiotics in Norway are used in primary care, i.e., in the community  
 201 outside hospitals (Figure 4); in addition, the contribution of the veterinary sector in total antibiotics  
 202 consumption is marginal (ECDC 2014; NORM/NORM-VET 2015). This leads to the assumption that  
 203 urban households play a major role in the induction or spread of antibiotic resistance in the municipal  
 204 sewage network being detected at the inlet of both WWTPs investigated.




Figure 4. Human usage (Defined Daily Doses, DDD, per 1000 inhabitants and per day) of antimicrobial agents (ATC group J01) for systemic use in Norway between 2008 and 2012 (source: ECDC 2014).

205  
 206 WWTPs display nodes where multiple wastewater streams from different sources with loads of  
 207 resistance-driving compounds and ARB & ARGs merge, and where the spread of anthropogenic-  
 208 derived antibiotic resistance to the environment can be controlled/improved, provided this is  
 209 technically feasible.

210 With caution, our limited set of results suggests that removal of ARB from wastewater could be  
 211 performed at the WWTPs rather than at hospitals. We also propose the removal of antibiotics at the  
 212 WWTPs as they are not currently removed by the present conventional treatment processes at the  
 213 investigated WWTPs (Thomas *et al.* 2007b). However, this may not necessarily exclude consideration  
 214 of implementing effluent point-treatment locally at the hospitals of multi-resistant ARB & ARGs,  
 215 specific clinical pathogens, and certain resistant-driving compounds, which are primarily hospital  
 216 based and prevail there at elevated concentrations (Kümmerer 2004; Thomas *et al.* 2007a; Langford  
 217 & Thomas 2009). Despite this knowledge, none of the hospitals in Oslo presently treats or separates  
 218 its wastewater effluent streams, even though much effort has been made during the past few years

219 to implement the ISO-14001 ecological standard that targets to minimize environmental pollution  
220 from hospitals.

221 For both WWTPs, the percentage of *E. coli* resistant to Tmp/Smx and Amp in the influent water is  
222 about two-fold higher than for Tet, while the percentage of Cip resistant *E. coli* is by far the lowest  
223 (Figure 3). Assuming a causal relationship of antibiotic concentration and resistance, this may explain  
224 the difference in the rate of antibiotic resistance observed. Related to antibiotic concentrations,  
225 Thomas and colleagues (2007b) detected lower concentrations of Tet and Cip in the influent of VEAS  
226 WWTP during 5 of 7 measurement incidences, while Tmp and Smx levels were always high. This  
227 behavior was explained by the properties of the antibiotics. Tet and Cip are more hydrophobic and  
228 tend to rapidly sorb to negatively charged particles compared to the more hydrophilic Tmp and Smx,  
229 which are less likely to adsorb to particles, and therefore remain in the water phase (Thomas *et al.*  
230 2007b) (adsorption coefficients are given in Table 2). Tet and Cip will then primarily accumulate in the  
231 sludge, while the other aqueous phase antibiotics are mobile through the downstream WWTP  
232 process, if they are not biodegraded or removed by other physical or chemical means (Thomas *et al.*  
233 2007b). It is therefore assumed that the lower aqueous phase concentrations of Tet and Cip may pose  
234 a lower selective pressure to develop resistance than the other two antibiotics. Moreover, ARB  
235 resistant to Tet and Cip will mainly be removed by the sludge sedimentation, leading to lower  
236 resistance rates for those agents. Due to sporadic peaks in Tet and Cip concentrations at the influent  
237 of WWTPs (Thomas *et al.* 2007b), occasionally elevated antibiotic resistance rates for those  
238 compounds could be anticipated. However, to solidify this assumption, more systematic investigations  
239 of the causal relationship of antibiotic concentration and resistance over time are needed.

240 In VEAS WWTP, the percentage of cultivable antibiotic resistant *E. coli* decreases in the physical and  
241 chemical treatment, while it does not decrease further by the biofilm process (Figure 3). Hence, it  
242 seems that the fraction of non-resistant *E. coli* is removed to a somewhat lower extent than the  
243 fraction of antibiotic resistant *E. coli*. Yet, due to the small number of samples, it remains unclear  
244 whether the decreased percentage of antibiotic resistant *E. coli* is significant or not. The total  
245 concentration of viable *E. coli* decreased by 2.4 log during the biofilm process and the percentage of  
246 resistant *E. coli* mostly remained unchanged. For BEVAS WWTP, the percentage of cultivable antibiotic  
247 resistant *E. coli* did not change considerably during the treatment processes, and this was independent  
248 of the antibiotic compound (Figure 3).

249 In spite of WWTPs significantly reducing the total concentration of *E. coli*, and consequently the  
250 relative fraction of antibiotic resistant organisms, data shows that full disinfection was not achieved.  
251 Therefore, it is assumed that the WWTPs release ARB to the receiving water body, the Oslofjord, to  
252 which WWTPs effluent are discharged at 30 to 55 m depths. The environmental impact on this  
253 ecosystem of ARB & ARGs and periodically high levels of some resistance-driving compounds, such as  
254 Tmp and Cip, being released into the fjord (Thomas *et al.* 2007b), is currently unknown due to lack of  
255 systematic and long-term studies. While a simple risk assessment has revealed that Cip containing  
256 effluent discharges by VEAS WWTP may at times pose an acute risk to certain aquatic organisms in  
257 the Oslofjord (Thomas *et al.* 2007a), uncertainty prevails if this is also true for ARB & ARGs, particularly  
258 due to the occurrence of Cip resistance in effluent samples from both WWTPs. Depending on the  
259 quantity and risk of WWTP discharges, they may pose a serious threat to the ecosystem, and may lead  
260 to a rising conflict with various other users potentially affected, such as bathing, fishing, and  
261 recreation.

262 **Membrane filtration removal effectivity.** UF and NF membranes were investigated by means of the  
263 membrane filtration test unit for their efficiency to remove antibiotic resistant *E. coli* from WWTP  
264 effluents. All membranes assessed removed viable *E. coli* completely below the limit of quantification


265 (10 CFU/mL) of the plating method illustrating that the membranes provide a potent hygienic barrier,  
266 as was expected (Figure 5, Table S1). The results from plating were confirmed by the MPN method,  
267 with no *E. coli* being detected (LOQ: 1 MPN/100 mL) in permeates of the UF (10 kDa) and the NF#2  
268 (150 Da) membranes (Krzeminski *et al.* 2017). The total removal effectiveness of viable *E. coli* in the  
269 untreated raw water by WWTP treatment combined with UF was > 4.2 log for both WWTPs. For the  
270 NF#1 membrane (200–400 Da), *E. coli* was found in the permeate (Krzeminski *et al.* 2017), but that  
271 was attributed to a sample contamination. The concentrate streams of membrane filtration contained  
272 almost the same concentration of *E. coli* as the feed, implying that those bacteria were accumulating  
273 in the concentrate streams during operation. Differences are attributed to the method's precision  
274 (Figure 5).

275


276 While the data suggest that ARB in WWTP effluent can be controlled by UF and NF, no conclusions can  
277 be made with regard to the destruction or removal of ARGs. However, ARGs are the main targets for  
278 disinfection as they display the main risk for spread of antibiotic resistance and are more difficult to  
279 destruct than ARB. For UF and NF membrane processes, ARG removal could be challenging because  
280 DNA is able to penetrate even through UF membranes due to its size, shape, and flexibility  
281 (Arkhangelsky *et al.* 2008; Arkhangelsky *et al.* 2011; Riquelme Breazeal *et al.* 2013). Riquelme and  
282 colleagues (2013) reported significant removal of ARGs spiked to WWTP effluents by means of  
283 membranes of 100 kDa and smaller. Interestingly, the interaction of DNA with wastewater colloidal  
284 particles enhanced the ARG removal by 10 kDa and 1 kDa membranes. The removal of *E. coli* during  
285 the present study and under the applied operational conditions is assumed to be due to size exclusion  
286 and cell-colloid interactions. However, for the NF experiments, other mechanisms such as electrostatic  
287 interactions with the membrane, may also play a role.

288

289 The results indicate that membrane filtration provides an additional barrier for ARB in wastewater  
290 treatment. Membrane filtration for ARB control may provide several key advantages compared to  
291 other methods as it removes particles and a range of other pollutants, including CECs (Krzeminski *et al.*  
292 2017); it provides stable and high quality effluent that can be tailored to the needs enabling fit-for-  
293 purpose approach; there is no need for continuous addition of disinfectants; no selection of  
294 resistance; it shows no formation of disinfection by-product; it has a small footprint, plant flexibility,  
295 is field proven, has long-term stability, and robustness. Conversely, based on current research, the  
296 challenges of membrane processes with regard to ARB & ARG removal include (i) possible penetration  
297 of DNA through the UF and NF membranes; (ii) unknown interaction of ARB & ARGs with biofilms  
298 developed on the membrane; (iii) handling of the waste stream containing ARB & ARGs in up-  
299 concentrated form; (iv) high energy consumption at large-scale application. Given that the presented  
300 results focused on ARB, future investigations need to clarify if and to what extent membranes provide  
301 a barrier for ARGs. Further research is required to confidently draw conclusions on whether  
302 membrane processes can provide a sufficient barrier for ARB & ARGs, either as stand-alone technology  
303 or as part of a multi-barrier treatment train.



a) VEAS WWTP



b) BEVAS WWTP

Figure 5. Concentrations of total viable *E. coli* (CFU/mL; boxes) and percentage (columns) of antibiotic resistant *E. coli* in the feed (i.e., WWTP effluent), permeate, and concentrate post-treatment with different membranes (UF = ultrafiltration; NF = nanofiltration). Feed samples were collected from (a) VEAS and (b) BEVAS WWTPs at different dates. Error bars represent 33% confidence interval (n=2).

305 **Conclusions**

306 The results of this study highlight that comparably high concentrations of viable *E. coli* resistance to  
307 the four antibiotics investigated occur in the effluent of both WWTPs. This suggests that urban  
308 households in the Oslo City area significantly contribute to the spread of antibiotic resistance in the  
309 municipal sewage network, which was detected at the inlet of the WWTPs. The relevance of these  
310 findings will need to be confirmed further by future investigations with more frequent sampling over  
311 longer terms including more statistical analysis. With regard to the relevance of WWTPs in the  
312 spreading of antibiotic resistance, it is important to unravel the causal relationship between antibiotic  
313 consumption, the antibiotics concentration in the wastewater streams of the entire WWTP (water and  
314 sludge), and the rate of antibiotic resistance amongst the prevailing populations. Although this  
315 relationship is described for clinical settings, this is not the case for the environment and requires  
316 further investigation.

317  
318 Besides a significant overall reduction of viable *E. coli* congruent to the reduction in the fraction of  
319 resistant bacteria across the treatment at both WWTPs, full disinfection of the final effluent by  
320 conventional treatment was not achieved and ARB were detected in the WWTP effluents. This may be  
321 critical, considering the release of ARB along with certain antibiotic resistance-driving compounds to  
322 the Oslofjord ecosystem. To ensure effective removal of ARB and ARG destruction in particular,  
323 adequate tertiary treatment methods will need to be assessed and verified for efficient functioning at  
324 full-scale.

325  
326 Consideration to the implementation of measures against ARB at WWTPs should include UF and NF,  
327 which may provide effective alternatives for the post-treatment of WWTP effluent to reduce the risk  
328 of ARB release to the receiving aquatic environment. Fortunately, this can be done in parallel with the  
329 removal of other pollutants. Yet, there is still uncertainty if this is also true for the removal of ARGs,  
330 thus further research is required given that ARGs are more difficult to remove and may require  
331 additional treatment of the permeate.

332 Even though WWTPs are major hotspots for the spread of antibiotic resistance, to date no technical  
333 measures have been introduced at WWTPs to minimize the problem. This may be due to the current  
334 lack of knowledge. In order for decision makers to judge the implementation of measures against the  
335 anthropogenic-induced spread of antibiotic resistance at WWTPs and relevant point-sources, an  
336 improved understanding of (i) the causal relationship of driving factors and organisms responsible for  
337 the spread of antibiotic resistance in full-scale WWTPs, (ii) the effect of the conventional and advanced  
338 treatment on those factors, and (iii) the fate and risk of ARB & ARGs spreading into the downstream  
339 environment, is required. In conclusion, further monitoring data, such as presented in this study and  
340 as outlined in the One Health approach (COM 2017), is required to better assess the risk of ARB &  
341 ARGs in wastewater treatment processes and to develop an action plan to manage the impact on  
342 human and animal health.

343  
344 **Acknowledgements**

345 The authors acknowledge the financial support from NIVA's Strategic Research Initiative on Emerging  
346 Environmental Contaminants (Research Council of Norway; contract no. 208430). The WWTPs  
347 Vestfjorden Avløpselskap and Bekkelaget Vann AS are kindly thanked for providing samples and for  
348 the fruitful collaboration. Two anonymous reviewers are kindly acknowledged for their constructive  
349 comments, which were of help to improve the manuscript.

350 **Supplementary Material**

351 Table S1. Concentrations of total viable *E. coli* from membrane experiments determined by the agar plating  
 352 method (LOQ: 10 CFU/mL). Numbers state average values  $\pm$  33% confidence interval (n=2).  
 353

| WWTP  | Membrane             | Sample location | cfu/mL       |
|-------|----------------------|-----------------|--------------|
| VEAS  | UF<br>(10 kDa)       | Feed            | 120 $\pm$ 18 |
|       |                      | Permeate        | <10          |
|       |                      | Concentrate     | 100          |
| BEVAS | UF<br>(10 kDa)       | Feed            | 140 $\pm$ 35 |
|       |                      | Permeate        | <10          |
|       |                      | Concentrate     | 75 $\pm$ 9   |
|       | NF#1<br>(200-400 Da) | Feed            | 110 $\pm$ 53 |
|       |                      | Permeate        | <10          |
|       |                      | Concentrate     | 55 $\pm$ 9   |
|       | NF#2<br>(150 Da)     | Feed            | 75 $\pm$ 44  |
|       |                      | Permeate        | <10          |
|       |                      | Concentrate     | 55 $\pm$ 9   |

354

355 **References**

356 Arkhangelsky E., Sefi Y., Hajaj B., Rothenberg G. & Gitis V. 2011. Kinetics and mechanism of plasmid  
 357 DNA penetration through nanopores. *Journal of Membrane Science*, **371**(1-2), 45-51.  
 358 Arkhangelsky E., Steubing B., Ben-Dov E., Kushmaro A. & Gitis V. 2008. Influence of pH and ionic  
 359 strength on transmission of plasmid DNA through ultrafiltration membranes. *Desalination*  
 360 **227**(1-3), 111-9.  
 361 Berendonk T. U., Manaia C. M., Merlin C., Fatta-Kassinos D., Cytryn E., Walsh F., Burgmann H., Sørum  
 362 H., Norstrøm M., Pons M. N., Kreuzinger N., Huovinen P., Stefani S., Schwartz T., Kisand V.,  
 363 Baquero F. & Martinez J. L. 2015. Tackling antibiotic resistance: the environmental framework.  
 364 *Nat Rev Microbiol*, **13**(5), 310-7.  
 365 Bockelmann U., Dorries H. H., Ayuso-Gabella M. N., Salgot de Marçay M., Tandoi V., Levantesi C.,  
 366 Masciopinto C., Van Houtte E., Szewzyk U., Wintgens T. & Grohmann E. 2009. Quantitative  
 367 PCR monitoring of antibiotic resistance genes and bacterial pathogens in three European  
 368 artificial groundwater recharge systems. *Appl Environ Microbiol*, **75**(1), 154-63.  
 369 Brenner K. P., Rankin C. C. & Sivaganesan M. 1996. Interlaboratory evaluation of MI agar and the US  
 370 Environmental Protection Agency-approved membrane filter method for the recovery of total  
 371 coliforms and *Escherichia coli* from drinking water. *Journal of Microbiological Methods*, **27**(2-  
 372 3), 111-9.  
 373 CLSI 2003. *Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-*  
 374 *A8*, Clinical and Laboratory Standards Institute, Wayne, PA.  
 375 CLSI 2012. M02-A11 Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved  
 376 Standard—Eleventh Edition. In, Clinical and Laboratory Standards Institute.  
 377 Colque Navarro P., Fernandez H., Mollby R., Otth L., Tiodolf M., Wilson M. & Kuhn I. 2014. Antibiotic  
 378 resistance in environmental *Escherichia coli* - a simple screening method for simultaneous  
 379 typing and resistance determination. *Journal of Water and Health*, **12**(4), 692-701.  
 380 COM 2017. *A European One Health Action Plan against Antimicrobial Resistance (AMR)*, European  
 381 Commission.  
 382 ECDC 2014. *Surveillance of antimicrobial consumption in Europe 2012*, European Centre for Disease  
 383 Prevention and Control Stockholm.  
 384 Eslamian S. (2016). *Urban water reuse handbook* CRC Press Taylor & Francis Group.  
 385 Krzeminski P., Schwermer C., Wennberg A., Langford K. & Vogelsang C. 2017. Occurrence of UV filters,  
 386 fragrances and organophosphate flame retardants in municipal WWTP effluents and their  
 387 removal during membrane post-treatment. *J Hazard Mater*, **323**(Pt A), 166-76.

388 Kümmerer K. 2004. Resistance in the environment. *Journal of Antimicrobial Chemotherapy*, **54**(2), 311-  
389 20.

390 Langford K. H. & Thomas K. V. 2009. Determination of pharmaceutical compounds in hospital effluents  
391 and their contribution to wastewater treatment works. *Environment International*, **35**(5), 766-  
392 70.

393 Michael I., Rizzo L., McArdell C. S., Manaia C. M., Merlin C., Schwartz T., Dagot C. & Fatta-Kassinos D.  
394 2013. Urban wastewater treatment plants as hotspots for the release of antibiotics in the  
395 environment: A review. *Water Research*, **47**(3), 957-95.

396 NIPH 2015. *Surveillance of resistant bacteria Yearly report 2015* Norwegian Institute of Public Health.

397 NMHCS 2015. *National Strategy against Antibiotic Resistance 2015–2020*. Norwegian Ministry of  
398 Health and Care Services.

399 NORM/NORM-VET 2015. *Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance*  
400 *in Norway*, Tromsø / Oslo 2016.

401 Riquelme Breazeal M. V., Novak J. T., Vikesland P. J. & Pruden A. 2013. Effect of wastewater colloids  
402 on membrane removal of antibiotic resistance genes. *Water Research*, **47**(1), 130-40.

403 Rizzo L., Manaia C., Merlin C., Schwartz T., Dagot C., Ploy M. C., Michael I. & Fatta-Kassinos D. 2013.  
404 Urban wastewater treatment plants as hotspots for antibiotic resistant bacteria and genes  
405 spread into the environment: A review. *Science of the Total Environment*, **447**, 345-60.

406 Storhaug R. 2014. *Increasing the capacity wastewater treatment plants in Oslo by process transitions*  
407 *during high flows - PREPARED 2014.030*.

408 Thomas K. V., Dye C., Schlabach M. & Langford K. H. 2007a. Source to sink tracking of selected human  
409 pharmaceuticals from two Oslo city hospitals and a wastewater treatment works. *Journal of*  
410 *Environmental Monitoring*, **9**(12), 1410-8.

411 Thomas K. V., Langford K. H., Grung M., Schlabach M. & Dye C. 2007b. *Occurrence of selected*  
412 *pharmaceuticals in wastewater effluents from hospitals (Ullevål and Rikshospitalet) and VEAS*  
413 *wastewater treatment works (TA-2246/2007)*, Norwegian Environment Agency, Oslo, Norway.

414 Tiodolf A. M., Annadotter H., Jenkins A., Midtvedt T. & Kühn I. 2013. *Screening for antibiotic-resistant*  
415 *bacteria in sewage and surface water in Oslo*, Regionale Forskningsfond Hovedstaden.

416 Verlicchi P., Al Aukidy M., Galletti A., Petrovic M. & Barcelo D. 2012. Hospital effluent: investigation of  
417 the concentrations and distribution of pharmaceuticals and environmental risk assessment.  
418 *Sci Total Environ*, **430**, 109-18.

419 Watkinson A. J., Micalizzi G. R., Bates J. R. & Costanzo S. D. 2007. Novel method for rapid assessment  
420 of antibiotic resistance in *Escherichia coli* isolates from environmental waters by use of a  
421 modified chromogenic agar. *Appl Environ Microbiol*, **73**(7), 2224-9.

422 WHO 2014. *Antimicrobial Resistance - Global Report on surveillance*, World Health Organization,  
423 Geneva.

424



